دورية أكاديمية
أعرض في EDS

Plasma metabolomics of oral squamous cell carcinomas based on NMR and MS approaches provides biomarker identification and survival prediction.

التفاصيل البيبلوغرافية
العنوان: Plasma metabolomics of oral squamous cell carcinomas based on NMR and MS approaches provides biomarker identification and survival prediction.
المؤلفون: Polachini GM; Department of Molecular Biology, School of Medicine of São José Do Rio Preto - FAMERP, Av. Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto, SP, CEP 15090-000, Brazil., de Castro TB; Department of Molecular Biology, School of Medicine of São José Do Rio Preto - FAMERP, Av. Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto, SP, CEP 15090-000, Brazil., Smarra LFS; Department of Molecular Biology, School of Medicine of São José Do Rio Preto - FAMERP, Av. Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto, SP, CEP 15090-000, Brazil.; Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, SP, Brazil., Henrique T; Department of Molecular Biology, School of Medicine of São José Do Rio Preto - FAMERP, Av. Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto, SP, CEP 15090-000, Brazil., de Paula CHD; Department of Molecular Biology, School of Medicine of São José Do Rio Preto - FAMERP, Av. Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto, SP, CEP 15090-000, Brazil., Severino P; Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil., López RVM; Center for Translational Research in Oncology, Institute of Cancer of São Paulo State, São Paulo, SP, Brazil., Carvalho AL; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil., de Mattos Zeri AC; Ilum School of Science, Brazilian Center for Research in Energy and Materials - CNPEM, Campinas, SP, Brazil., Silva IDCG; Department of Gynecology, Federal University of São Paulo, São Paulo, SP, Brazil.; Fleury Laboratories, São Paulo, SP, Brazil., Tajara EH; Department of Molecular Biology, School of Medicine of São José Do Rio Preto - FAMERP, Av. Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto, SP, CEP 15090-000, Brazil. tajara@famerp.br.; Department of Genetics and Evolutionary Biology, Institute of Biosciences, University of São Paulo, São Paulo, SP, Brazil. tajara@famerp.br.
المصدر: Scientific reports [Sci Rep] 2023 May 26; Vol. 13 (1), pp. 8588. Date of Electronic Publication: 2023 May 26.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Carcinoma, Squamous Cell*/pathology , Mouth Neoplasms*/pathology , Head and Neck Neoplasms*, Humans ; Squamous Cell Carcinoma of Head and Neck ; Biomarkers, Tumor/metabolism ; Metabolomics/methods ; Magnetic Resonance Spectroscopy ; Tumor Microenvironment
مستخلص: Metabolomics has proven to be an important omics approach to understand the molecular pathways underlying the tumour phenotype and to identify new clinically useful markers. The literature on cancer has illustrated the potential of this approach as a diagnostic and prognostic tool. The present study aimed to analyse the plasma metabolic profile of patients with oral squamous cell carcinoma (OSCC) and controls and to compare patients with metastatic and primary tumours at different stages and subsites using nuclear magnetic resonance and mass spectrometry. To our knowledge, this is the only report that compared patients at different stages and subsites and replicates collected in diverse institutions at different times using these methodologies. Our results showed a plasma metabolic OSCC profile suggestive of abnormal ketogenesis, lipogenesis and energy metabolism, which is already present in early phases but is more evident in advanced stages of the disease. Reduced levels of several metabolites were also associated with an unfavorable prognosis. The observed metabolomic alterations may contribute to inflammation, immune response inhibition and tumour growth, and may be explained by four nonexclusive views-differential synthesis, uptake, release, and degradation of metabolites. The interpretation that assimilates these views is the cross talk between neoplastic and normal cells in the tumour microenvironment or in more distant anatomical sites, connected by biofluids, signalling molecules and vesicles. Additional population samples to evaluate the details of these molecular processes may lead to the discovery of new biomarkers and novel strategies for OSCC prevention and treatment.
(© 2023. The Author(s).)
References: Metabolites. 2019 Jun 08;9(6):. (PMID: 31181753)
Int J Clin Exp Pathol. 2015 Jul 01;8(7):7967-77. (PMID: 26339363)
J Proteome Res. 2011 Nov 4;10(11):5232-41. (PMID: 21961579)
Head Neck. 2011 Aug;33(8):1092-8. (PMID: 20967872)
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):287-295. (PMID: 34939358)
Annu Rev Nutr. 2017 Aug 21;37:51-76. (PMID: 28826372)
Int J Cancer. 2014 Oct 1;135(7):1711-20. (PMID: 24615175)
PLoS One. 2018 Sep 20;13(9):e0204249. (PMID: 30235319)
Nat Methods. 2020 Jan;17(1):24. (PMID: 31907484)
Genes Dev. 2013 Oct 1;27(19):2065-71. (PMID: 24115766)
Front Psychiatry. 2021 Nov 30;12:781668. (PMID: 34916977)
Cell. 2016 Oct 20;167(3):829-842.e13. (PMID: 27745970)
Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405. (PMID: 26122615)
Am J Physiol Endocrinol Metab. 2014 Jun 15;306(12):E1378-87. (PMID: 24760988)
Biomolecules. 2020 Apr 08;10(4):. (PMID: 32276408)
Sci Rep. 2016 Dec 08;6:38299. (PMID: 27929071)
Neoplasia. 2009 Mar;11(3):269-76, 4p following 269. (PMID: 19242608)
Oral Oncol. 2017 Apr;67:175-182. (PMID: 28351574)
Cancer Cell. 2004 May;5(5):489-500. (PMID: 15144956)
Alcohol Clin Exp Res. 2021 Apr;45(4):666-674. (PMID: 33576525)
Cell Metab. 2016 Jan 12;23(1):27-47. (PMID: 26771115)
J Lipid Res. 2016 Jun;57(6):943-54. (PMID: 27080715)
J Clin Lipidol. 2018 Mar - Apr;12(2):311-320.e3. (PMID: 29246731)
Molecules. 2021 Oct 19;26(20):. (PMID: 34684890)
Expert Opin Ther Targets. 2010 May;14(5):529-39. (PMID: 20334489)
Cancer Metastasis Rev. 2011 Dec;30(3-4):567-76. (PMID: 22005951)
Cell Cycle. 2010 Sep 1;9(17):3506-14. (PMID: 20818174)
J Sci Med Sport. 2017 Jul;20(7):700-705. (PMID: 28185807)
J Natl Cancer Inst. 2014 Dec 16;107(1):398. (PMID: 25515231)
Nature. 2006 May 25;441(7092):424-30. (PMID: 16724053)
Sci Rep. 2020 Dec 14;10(1):21836. (PMID: 33318510)
Cell Metab. 2022 Mar 1;34(3):355-377. (PMID: 35123658)
PLoS One. 2018 Jul 12;13(7):e0200140. (PMID: 30001359)
Science. 2013 Jan 11;339(6116):211-4. (PMID: 23223453)
Cell Metab. 2021 Sep 7;33(9):1744-1762. (PMID: 34496230)
Biochem Biophys Res Commun. 2018 Jan 1;495(1):761-767. (PMID: 29146184)
PLoS One. 2011 Feb 16;6(2):e16957. (PMID: 21359215)
Cells. 2022 Jan 09;11(2):. (PMID: 35053330)
Head Neck. 2002 Aug;24(8):766-72. (PMID: 12203802)
JCI Insight. 2017 Feb 23;2(4):e87489. (PMID: 28239646)
Nat Commun. 2019 Jul 5;10(1):3000. (PMID: 31278254)
Mol Oncol. 2019 May;13(5):1002-1017. (PMID: 30628163)
Cancer Res. 2004 Jun 1;64(11):3892-9. (PMID: 15172999)
Ann Oncol. 2019 Jan 1;30(1):68-75. (PMID: 30407504)
Neurology. 2022 Feb 1;98(5):e493-e505. (PMID: 34845055)
Curr Genet Med Rep. 2017 Sep;5(3):132-142. (PMID: 29177110)
J Emerg Med. 2021 Dec;61(6):658-665. (PMID: 34711442)
Obes Sci Pract. 2021 May 04;7(5):646-656. (PMID: 34631141)
Prog Lipid Res. 2018 Jul;71:18-42. (PMID: 29746894)
J Membr Biol. 2018 Dec;251(5-6):609-631. (PMID: 30350011)
Amino Acids. 2021 Oct;53(10):1589-1595. (PMID: 34550462)
Cancer Causes Control. 2020 Feb;31(2):113-126. (PMID: 31828464)
Int J Cancer. 2021 Apr 5;:. (PMID: 33818764)
Nat Rev Cancer. 2018 May;18(5):269-282. (PMID: 29497144)
Br J Cancer. 2019 Jun;120(12):1090-1098. (PMID: 31092908)
Int J Mol Sci. 2021 Jun 11;22(12):. (PMID: 34208417)
Nat Rev Cancer. 2019 Nov;19(11):625-637. (PMID: 31515518)
J Inherit Metab Dis. 2014 Jul;37(4):541-51. (PMID: 24706027)
Clin Chem. 2016 May;62(5):755-65. (PMID: 26980210)
Nat Rev Cancer. 2011 Jan;11(1):9-22. (PMID: 21160525)
Nat Protoc. 2011 Jun;6(6):743-60. (PMID: 21637195)
J Proteome Res. 2017 May 5;16(5):1847-1856. (PMID: 28345344)
Biochem Biophys Res Commun. 2021 Dec 31;585:61-67. (PMID: 34794035)
Mol Cell. 2021 Sep 16;81(18):3731-3748. (PMID: 34547236)
Cancer Lett. 2007 Oct 18;256(1):101-11. (PMID: 17619081)
Biochem Biophys Res Commun. 2015 Apr 17;459(4):574-8. (PMID: 25769954)
Membranes (Basel). 2021 Oct 16;11(10):. (PMID: 34677553)
Clin Biochem. 2013 Oct;46(15):1447-52. (PMID: 23697717)
Protein Cell. 2018 Feb;9(2):216-237. (PMID: 28748451)
Cell Metab. 2017 Feb 7;25(2):345-357. (PMID: 28111214)
Nutrients. 2019 Oct 01;11(10):. (PMID: 31581552)
Metabolites. 2017 May 16;7(2):. (PMID: 28509845)
Int J Biochem Cell Biol. 2012 Nov;44(11):1852-61. (PMID: 22743333)
Exp Eye Res. 2021 Feb;203:108401. (PMID: 33326810)
Nat Commun. 2018 Apr 10;9(1):1368. (PMID: 29636461)
Cell Rep. 2018 Oct 16;25(3):663-676.e6. (PMID: 30332646)
Crit Care Clin. 2012 Oct;28(4):601-31. (PMID: 22998993)
Cell. 2017 May 4;169(4):570-586. (PMID: 28475890)
N Engl J Med. 2007 Dec 20;357(25):2552-61. (PMID: 18094376)
J Leukoc Biol. 2016 Feb;99(2):387-98. (PMID: 26497246)
Front Immunol. 2022 Aug 25;13:955614. (PMID: 36090994)
In Vivo. 2018 Mar-Apr;32(2):425-429. (PMID: 29475932)
Adv Exp Med Biol. 2014;816:107-27. (PMID: 24818721)
Exp Biol Med (Maywood). 2008 Jun;233(6):674-88. (PMID: 18408140)
Oncogenesis. 2016 Feb 22;5:e200. (PMID: 26900952)
Med Sci Monit. 2018 May 09;24:3034-3041. (PMID: 29741162)
Metabolites. 2019 Dec 14;9(12):. (PMID: 31847385)
Nature. 2020 Sep;585(7824):277-282. (PMID: 32879489)
Nat Rev Cancer. 2016 Oct;16(10):650-62. (PMID: 27634448)
Adv Exp Med Biol. 2018;1112:141-149. (PMID: 30637695)
Eur Arch Otorhinolaryngol. 2018 May;275(5):1239-1247. (PMID: 29520497)
J Biol Chem. 1999 Oct 15;274(42):29683-8. (PMID: 10514439)
Science. 2017 Nov 17;358(6365):941-946. (PMID: 29025995)
Biochim Biophys Acta. 2016 Oct;1863(10):2422-35. (PMID: 26828774)
Nat Rev Cancer. 2018 Oct;18(10):634-645. (PMID: 30194362)
Metabolites. 2019 Jun 27;9(7):. (PMID: 31252628)
Cell Metab. 2018 Nov 6;28(5):721-736.e6. (PMID: 30122553)
Cell Physiol Biochem. 2015;35(1):364-73. (PMID: 25591777)
Metabolomics. 2019 Aug 16;15(8):110. (PMID: 31420744)
Cell Metab. 2017 Feb 7;25(2):262-284. (PMID: 28178565)
Eur J Endocrinol. 2019 Dec;181(6):647-657. (PMID: 31614337)
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:499-505. (PMID: 30008306)
Lab Med. 2020 Nov 2;51(6):566-573. (PMID: 32161964)
J Proteomics. 2020 Feb 20;213:103605. (PMID: 31841666)
Ann Nutr Metab. 2012;60(1):17-26. (PMID: 22212454)
Nat Rev Cancer. 2018 Jan;18(1):33-50. (PMID: 29147025)
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191. (PMID: 29165427)
Oral Oncol. 2021 Apr;115:105184. (PMID: 33581504)
Clin Chim Acta. 2009 Mar;401(1-2):8-13. (PMID: 19056370)
Ann Transl Med. 2018 Dec;6(24):471. (PMID: 30740402)
Nutrients. 2020 Jan 12;12(1):. (PMID: 31940925)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
J Steroid Biochem Mol Biol. 2018 Apr;178:312-321. (PMID: 29360580)
J Proteome Res. 2017 Mar 3;16(3):1315-1326. (PMID: 28168879)
Front Cell Dev Biol. 2021 Jan 12;8:603837. (PMID: 33511116)
Metabolomics. 2020 Sep 30;16(10):105. (PMID: 33000429)
Clin Chim Acta. 2015 Feb 20;441:47-55. (PMID: 25499120)
Nat Rev Cancer. 2021 Dec;21(12):753-766. (PMID: 34417571)
Ann Surg Oncol. 2022 Nov;29(12):7386-7399. (PMID: 35829796)
Prostate. 2016 Sep;76(12):1106-19. (PMID: 27197810)
Int J Cancer. 2011 Nov 1;129(9):2207-17. (PMID: 21190195)
PLoS One. 2008 Jul 16;3(7):e2722. (PMID: 18628958)
Cell Rep. 2019 Sep 17;28(12):3011-3021.e4. (PMID: 31533027)
Dis Markers. 2021 May 19;2021:5558458. (PMID: 34113404)
Semin Cell Dev Biol. 2017 Apr;64:125-131. (PMID: 27833036)
Semin Pediatr Neurol. 2008 Sep;15(3):140-9. (PMID: 18708005)
Metabolomics. 2010 Mar;6(1):78-95. (PMID: 20300169)
J Lipid Res. 2016 Nov;57(11):2028-2039. (PMID: 27623848)
Int J Mol Sci. 2013 Jul 04;14(7):13893-908. (PMID: 23880848)
Front Immunol. 2022 Feb 15;13:768606. (PMID: 35250970)
Nat Genet. 2021 Jan;53(1):16-26. (PMID: 33414552)
Crit Rev Biochem Mol Biol. 2013 Jan-Feb;48(1):20-38. (PMID: 23350810)
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20230526 Date Completed: 20230529 Latest Revision: 20230609
رمز التحديث: 20230609
مُعرف محوري في PubMed: PMC10220089
DOI: 10.1038/s41598-023-34808-2
PMID: 37237049
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-023-34808-2